新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Celgene与Array签订抗炎症研究协议

Celgene与Array签订抗炎症研究协议

来源:生物谷 2013-07-30 22:34

2013年7月30日讯 /生物谷BIOON/ --Celgene公司与Array公司达成了一项价值1100万美元的协议,在抗炎症领域中结成合作伙伴关系,合作研究揭示炎症的成因。Celgene公司近年来已经和很多企业合作在炎症领域进行深入研究,这次的协议只是其中之一。但双方并未透露合约中涉及的新药的研究情况和机理。(生物谷Bioon.com)

详细英文报道:

Array BioPharma ($ARRY) has pocketed $11 million from Celgene for a preclinical-stage partnership to discover drugs against an undisclosed cause of inflammation. The heavily back-ended payment schedule for the deal includes up to $376 million in payments from Celgene ($CELG) based on the success of drug candidates from Array, which also stands to gain royalty checks on potential winners.

Celgene has spread its bets widely across a number of external groups working on discovering drugs for inflammation and cancer. And the arrangement with Array represents a relatively small upfront bet for the Summit, NJ-based biotech powerhouse, which has just forked over $100 million for an option to buy Acetylon and the Boston startup's HDAC6 inhibitor in early clinical development for myeloma.

Array is also active on the partnership scene and has relied on collaborators such as Roche ($RHHBY) and Novartis ($NVS) to advance some of its leading drug candidates in oncology. The company also just revealed upbeat midstage data in asthma patients for an oral CRTh2 antagonist called ARRY-502, which could be one of the Boulder, CO-based developer's next assets for a partnership. That is the company's hope.

Celgene and Array did not disclose the details of the inflammation pathway involved in their new collaboration. Yet clinical trials have validated Array's ability to discover small-molecule compounds with activity against causes of inflammation and pain.

"Given Celgene's global leadership and expertise in the development and commercialization of innovative therapies and Array's solid track record of inventing and progressing targeted drugs into clinical trials," Array Chief Scientific Officer Kevin Koch stated, "we believe this alliance will maximize the value of a very exciting and innovative program."

Array has the right to take over development of any compounds from the alliance that Celgene opts not to pursue. Shares of Array jumped 7% to $6.70 per share in after-hours trading Monday.

 

本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库